Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The adenosine receptors are a family of four distinct G protein-coupled receptors—designated as the adenosine receptor subtypes: Adenosine receptor type 1, type 2a, type 2b, and type 3. Each subtype is encoded by a separate gene and exhibits unique tissue distributions and physiological roles. These receptors mediate the diverse biological actions of extracellular adenosine throughout the body—including modulation of neurotransmission in the brain; regulation of heart rate, myocardial oxygen consumption, coronary blood flow; control over inflammatory processes; influence on cell proliferation/apoptosis; and involvement in metabolic diseases such as diabetes. Pharmacologically important both as direct drug targets—such as with selective agonists/antagonists—and indirectly through widely consumed substances like caffeine that act primarily by blocking these receptors. Selectivity among subtypes allows for targeted therapies—for instance, antagonism at the adenosine A_2a_ subtype has been developed for Parkinson’s disease treatment while other subtypes are being explored for cancer immunotherapy or autoimmune disorders. Their ubiquitous presence makes them central players in many pathophysiological conditions but also presents challenges regarding specificity and safety during therapeutic intervention.[5][3][4][7]
Agonists activate the receptors to modulate cAMP levels via G protein signaling pathways; effects depend on subtype and tissue distribution. * For example: * Activation of A1 or A3 receptors inhibits adenylyl cyclase via Gi/o proteins → decreases cAMP. * Activation of A2A or A2B stimulates adenylyl cyclase via Gs proteins → increases cAMP.[3][4][7] * Antagonists block these effects; e.g., caffeine blocks the sedative/cardiodepressant actions by antagonizing ARs.[5]
5 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Adenosine receptor (A1, A2A, A2B, and A3 subtypes) (AR (with subtype-specific abbreviations: A1AR, A2AAR, A2BAR, A3AR)).